# ZC3H12B

## Overview
ZC3H12B is a gene that encodes the protein zinc finger CCCH-type containing 12B, also known as MCPIP2, which is a member of the ZC3H12 protein family. This protein is characterized by the presence of a NYN/PIN domain and a CCCH-type zinc finger, which are essential for its function in mRNA turnover and regulation. ZC3H12B is primarily involved in the degradation of specific mRNA transcripts, such as interleukin-6 (IL-6), by binding to their 3' untranslated regions and facilitating their degradation. This ribonucleolytic activity is crucial for its role as a negative regulator of cell proliferation, particularly by stalling the cell cycle in the G2 phase. ZC3H12B is highly expressed in neural tissues, suggesting a significant role in the brain, and has been implicated in the prognosis of glioma and chronic lymphocytic leukemia. Its interactions with other mRNA targets and involvement in inflammatory responses underscore its potential as a prognostic marker and therapeutic target in cancer (Wawro2019ZC3H12BMCPIP2; Fernández‐Martínez2017Genomic; Chen2021Identification).

## Structure
The ZC3H12B protein is characterized by the presence of an NYN/PIN domain, which is crucial for its ribonucleolytic activity. This domain contains four conserved aspartic acid residues essential for binding magnesium ions, a requirement for its enzymatic function (Wawro2019ZC3H12BMCPIP2). The NYN/PIN domain is aligned with that of Regnase-1/ZC3H12A/MCPIP1, indicating a conserved and potentially functional nuclease domain (Wawro2019ZC3H12BMCPIP2). Adjacent to the NYN/PIN domain is a CCCH-type zinc finger, which plays a significant role in binding target RNAs (Wawro2019ZC3H12BMCPIP2).

The protein forms granule-like structures in the cytoplasm, which is indicative of its role in mRNA turnover (Wawro2019ZC3H12BMCPIP2). The NYN/PIN domain is also essential for ZC3H12B's ability to inhibit cell proliferation by stalling the cell cycle in the G2 phase (Wawro2019ZC3H12BMCPIP2). The protein's structure is critical for its function, as a point mutation in the NYN/PIN domain that disrupts magnesium ion binding abolishes its activity (Wawro2019ZC3H12BMCPIP2). While the context does not provide detailed information on the complete molecular structure, these domains are integral to the protein's function in mRNA regulation and cell cycle control.

## Function
The ZC3H12B gene encodes a protein that is part of the ZC3H12 family, known for its role in mRNA turnover and regulation. ZC3H12B is a cytoplasmic protein that forms granule-like structures and is involved in the degradation of specific mRNA transcripts, such as interleukin-6 (IL-6), by binding to their 3' untranslated regions (UTRs) and accelerating their degradation (Wawro2019ZC3H12BMCPIP2). This activity is mediated by its NYN/PIN domain, which is crucial for its ribonucleolytic function (Wawro2019ZC3H12BMCPIP2).

In healthy human cells, ZC3H12B acts as a negative regulator of cell proliferation and is involved in maintaining cellular homeostasis. Overexpression of ZC3H12B has been shown to inhibit cell proliferation by stalling the cell cycle in the G2 phase, a process dependent on its nuclease activity (Wawro2019ZC3H12BMCPIP2). ZC3H12B is highly expressed in the human brain and the neuroblastoma cell line SH-SY5Y, suggesting a role in neural tissues (Wawro2019ZC3H12BMCPIP2). It also regulates the expression of other mRNA targets, such as IER3 and Regnase-1, indicating its involvement in modulating inflammatory responses and cell proliferation (Wawro2019ZC3H12BMCPIP2).

## Clinical Significance
ZC3H12B, also known as MCPIP2, has been implicated in the prognosis of glioma, a type of brain tumor. The gene is part of a group of RNA-binding proteins (RBPs) that are differentially expressed in glioma and are associated with immune function and the tumor microenvironment. High-risk glioma patients often exhibit upregulation of immune gene sets, yet they experience worse prognoses due to immunosuppression. ZC3H12B is noted for its ability to negatively regulate NFκB, which affects cell proliferation, survival, and differentiation, linking its expression to the risk score and prognosis in glioma (Chen2021Identification).

In the context of chronic lymphocytic leukemia (CLL), ZC3H12B has been identified as a potential discriminatory gene through frequency analysis, suggesting its involvement in the disease. However, specific clinical implications of ZC3H12B mutations or expression changes in CLL are not detailed (Fernández‐Martínez2017Genomic).

Overall, alterations in ZC3H12B expression or its interactions may contribute to the progression of certain cancers, highlighting its potential as a prognostic marker and therapeutic target. However, detailed clinical outcomes related to specific mutations or expression changes in ZC3H12B remain to be fully elucidated.

## Interactions
ZC3H12B, a member of the ZC3H12 protein family, is involved in interactions with both proteins and nucleic acids. It is known to bind to interleukin-6 (IL-6) mRNA, regulating its turnover and reducing IL-6 protein production upon stimulation with IL-1β. This interaction occurs through the binding of ZC3H12B to the stem-loop structure in the IL-6 3' UTR, highlighting its role in mRNA destabilization (Wawro2019ZC3H12BMCPIP2).

ZC3H12B also interacts with other substrates of the ZC3H12 family, such as IER3 mRNA, and is associated with endogenous IL-6 and IER3 transcripts in vivo. However, it does not strongly interact with Regnase-1 transcripts in HeLa cells, suggesting substrate specificity (Wawro2019ZC3H12BMCPIP2).

The protein forms granule-like structures in the cytoplasm, typical of proteins involved in mRNA turnover, and its ribonucleolytic activity is crucial for its biological effects. Overexpression of ZC3H12B has been shown to inhibit cell proliferation by stalling the cell cycle in the G2 phase, a process dependent on its NYN/PIN domain (Wawro2019ZC3H12BMCPIP2).


## References


[1. (Chen2021Identification) Zhuohui Chen, Haiyue Wu, Haojun Yang, Yishu Fan, Songfeng Zhao, and Mengqi Zhang. Identification and validation of rna‐binding protein‐related gene signature revealed potential associations with immunosuppression and drug sensitivity in glioma. Cancer Medicine, 10(20):7418–7439, September 2021. URL: http://dx.doi.org/10.1002/cam4.4248, doi:10.1002/cam4.4248. This article has 15 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/cam4.4248)

[2. (Wawro2019ZC3H12BMCPIP2) Mateusz Wawro, Karolina Wawro, Jakub Kochan, Aleksandra Solecka, Weronika Sowinska, Agata Lichawska-Cieslar, Jolanta Jura, and Aneta Kasza. Zc3h12b/mcpip2, a new active member of the zc3h12 family. RNA, 25(7):840–856, April 2019. URL: http://dx.doi.org/10.1261/rna.071381.119, doi:10.1261/rna.071381.119. This article has 26 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1261/rna.071381.119)

[3. (Fernández‐Martínez2017Genomic) Juan Luis Fernández‐Martínez, Enrique J. deAndrés‐Galiana, and Stephen T. Sonis. Genomic data integration in chronic lymphocytic leukemia. The Journal of Gene Medicine, January 2017. URL: http://dx.doi.org/10.1002/jgm.2936, doi:10.1002/jgm.2936. This article has 21 citations.](https://doi.org/10.1002/jgm.2936)